Key Developments For Clarient, Inc.
Clarient, Inc. (CLRT.O) (Consolidated Issue listed on NASDAQ Capital Market)
Clarient, Inc. Lowers FY 2009 Revenue Guidance
Clarient, Inc. lowered revenue guidance for fiscal 2009 to $90 to $94 million from the previous range of $96 to $101 million. According to Reuters Estimates, analysts on an average were expecting the Company to report revenue of $98 million for the same period.
Clarient, Inc. Raises FY 2009 Revenue Guidance; Comments On FY 2009 Earnings Guidance
Clarient, Inc. increased its guidance for fiscal 2009 and expects revenue to the range of $96-$101 million, as well as positive adjusted EBITDA and operating income. According to Reuters Estimates, analysts were expecting the Company to report revenue of $97 million, EBITDA of $12.10 million and EBIT of $6.02 million for fiscal 2009.
Safeguard Scientifics, Inc. Portfolio Company Clarient, Inc. Files Form S-3 Registration Statement
Safeguard Scientifics, Inc. announced that its portfolio company Clarient, Inc. has filed a registration statement with the Securities and Exchange Commission on Form S-3 relating to shares of the Company owned by Safeguard. Safeguard owned 60% of the Company's outstanding shares at December 31, 2008 and approximately 50% on an as-converted basis at March 31, 2009 after the closing of the first tranche of the Company's private placement of $40 million in convertible preferred stock with Oak Investment Partners. With the completion of the second tranche of the private placement on May 14, 2009, Oak now has effective control of approximately 21% of the Company outstanding shares on an as converted basis, reducing Safeguard`s ownership position to approximately 47%.
Clarient, Inc. Launches New Gene Mutation Test to Help Select Therapy for Non-Small Cell Lung Cancer
Clarient, Inc. announced the launch of a new gene mutation test that can help physicians select the proper therapy for patients with non-small cell lung cancer (NSCLC). The test, called epidermal growth factor receptor (EGFR) mutation, has been validated as a laboratory-developed test and is now available to physicians and their patients.
Clarient, Inc. Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
Clarient, Inc. announced that it has completed the second tranche of a private placement of convertible preferred stock with Oak Investment Partners, a multi-stage venture capital firm based in Westport, CT. The second tranche for approximately $10.9 million, combined with $29.1 million in proceeds from the first tranche that closed March 26, 2009, will retire $31 million in Clarient borrowings and bolster working capital.
